Personalised decision support for insulin-treated diabetes
Smart app provides prognoses and information
The solution is an app that can predict dangerously high or low blood sugar levels, and that is currently heading for clinical testing and commercialisation.
The app developed by Fredrik Ståhl communicates with a sensor of the same type as the one already used by a growing number of patients with an insulin pump for dosing insulin. The sensor is a small thread located in the subcutaneous fat of the abdomen, and is called CGM: Continuous Glucose Monitoring.
“The big news is that the app operates based on a self-learning algorithm in a cloud service that can provide personalised prognoses: If I eat a pizza and take this or that much insulin, what will my blood sugar level be like in a few hours? This is just the kind of information we want but have not been able to get so far”, says Fredrik.
The algorithms are based on research results which he developed during his time as a researcher.
The fear of all diabetics
Fredrik has plenty of personal experience of how great the need for reliable and personalised functioning decision support really is:
“As a diabetic, you measure your blood sugar in all conceivable contexts. It can be before or after a meal or a workout, and not least before bedtime, so as not to have dangerously low blood sugar when sleeping. All people with insulin treatment are afraid of this.”
“The measurement provides some information, but it really comes down to how well you know your own body.”
Approved for patent application
There are thousands of apps for diabetics on the market, but they provide little or no concrete help, says Fredrik.
“They are more like journals or general fact-gathering.”
However, his company, Dianovator, has received the green light on all counts by the Patent Cooperation Treaty, the international body that reviews inventions for patent applications:
“They assess the novelty value, technical level and marketability of the invention.”
Compatible with an established sensor
After the initial and, according to Fredrik Ståhl, crucial funding from Swelife, Dianovator recently received external funding allowing the team to proceed. Clinical testing will begin this spring and the commercial launch of the Android and iOS app could take place next autumn.
“Over 400 million people have diabetes. Most have type 2, but eventually they too need insulin. The CGM sensors are already established on the market and, lately, their prescription has greatly accelerated. When our app is launched, it will provide decision support that increases the value of the sensors. We believe that the two will boost each other”, says Fredrik Ståhl.
Updated: 16 October 2017
Text: Jörgen Olsson